ArticleAAPS PharmSciTech2010
Formulation of a novel oxybenzone-loaded nanostructured lipid carriers (NLCs).
Article in AAPS PharmSciTech, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 145 citations in OpenAlex.
- The Tiny Big Difference: Nanotechnology in Photoprotective Innovations - A Systematic Review.AAPS PharmSciTech · 2024Pooled it
- Nano-Engineered Cargo for Optimizing Oral Absorption of Tizanidine Nanostructured Lipid Carriers.Advanced pharmaceutical bulletin · 2025Article
- In-situ Nanolipoidal Gel of Stiripentol for Intranasal Administration: Preclinical Evidence of Enhanced Biopharmaceutical and Therapeutic Outcomes.AAPS PharmSciTech · 2025Article
- Lipid-based nanoformulations in onychomycosis therapy: addressing challenges of current therapies and advancing treatment.RSC advances · 2025Review
- Development and Optimization of Oral Dissolution Films for Enhanced Delivery of Ebastine-Loaded Solid Lipid Nanoparticles.International journal of nanomedicine · 2025Article
- Capecitabine-loaded NLC for Breast Cancer Treatment: Preparation, Characterization, andCurrent drug delivery · 2025Article
- Clinical Applications of Sunscreens and Formulation Advancements.Current drug research reviews · 2024Review
- Cod liver oil nano-structured lipid carriers (Cod-NLCs) as a promising platform for nose to brain delivery: Preparation,International journal of pharmaceutics: X · 2023Article
- Formulation and Characterization of Mupirocin Nanomicelles in Insulin-Based Gel for Dermatological Application.Journal of pharmacy & bioallied sciences · 2023Article
- Nanoparticles as a Therapeutic Delivery System for Skin Cancer Prevention and Treatment.JID innovations : skin science from molecules to population health · 2023Review
- Nanogel Containing Gamma-Oryzanol-Loaded Nanostructured Lipid Carriers and TiOPharmaceuticals (Basel, Switzerland) · 2023Article
- Tailoring Apixaban in Nanostructured Lipid Carrier Enhancing Its Oral Bioavailability and Anticoagulant Activity.Pharmaceutics · 2022Article
- The protective impact of adapted trimebutine maleate-loaded nanostructured lipid carriers for alleviating the severity of acute colitis.Drug delivery · 2022Article
- Polymeric versus lipid nanocapsules for miconazole nitrate enhanced topical delivery:Drug delivery · 2022Article
- Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout.BMC pharmacology & toxicology · 2022Article
- In Vitro and Ex Vivo Evaluation of Fluocinolone Acetonide-Acitretin-Coloaded Nanostructured Lipid Carriers for Topical Treatment of Psoriasis.Gels (Basel, Switzerland) · 2022Article
- Meropenem-Loaded Nanostructured Lipid Carriers For Skin and Soft Tissue Infection Caused by Staphylococcus aureus: Formulation, Design, and Evaluation.AAPS PharmSciTech · 2022Article
- Synthesis and Potential Applications of Lipid Nanoparticles in Medicine.Materials (Basel, Switzerland) · 2022Review
- Tailoring thixotropic mixed-lipid nanoconstructs of voriconazole for the management of Vulvovaginal candidiasis: Formulation, statistical optimization,Drug delivery · 2021Article
- Lipid-based nano-formulation platform for eplerenone oral delivery as a potential treatment of chronic central serous chorioretinopathy:Drug delivery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of the current study was to formulate oxybenzone into nanostructured lipid carriers (NLCs) to enhance its sunscreening efficacy and safety. NLCs of oxybenzone were prepared by the solvent diffusion method. A complete 2(3) factorial design was used for the evaluation of the prepared oxybenzone NLCs. The study design involves the investigation of the effect of three independent variables namely liquid lipid type (Miglyol 812 and oleic acid), liquid lipid concentration (15% and 30%), and oxybenzone concentration (5% and 10% with respect to total lipids) on the particle size (p.s.) , the entrapment efficiency (EE%) and the in vitro drug release after 8 h. The prepared NLCs were spherical in overall shape and were below 0.8 microm. Miglyol 812 and 30% liquid lipid were found to significantly decrease the p.s. and increase the EE% when compared to oleic acid and 15% liquid lipid. Increasing oxybenzone concentration increased significantly the p.s. but did not affect the EE%. NLCs prepared using Miglyol 812, 15% liquid lipid, and 10% oxybenzone showed slower drug release when compared to those prepared using oleic acid, 30% liquid lipid, and 5% oxybenzone, respectively. The candidate oxybenzone-loaded NLC dispersion was then formulated into gel. The incorporation of oxybenzone into NLCs greatly increased the in vitro sun protection factor and erythemal UVA protection factor of oxybenzone more than six- and eightfold, respectively, while providing the advantage of overcoming side effects of free oxybenzone as evidenced by very low irritation potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.